Cabaletta Bio, Inc. (CABA) intrinsic value & 10-year financials
Cabaletta Bio, Inc. (CABA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.41
- Market cap
- $112.7M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -175.9%
- Free cash flow (FY2025)
- -$132.3M
CABA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$167.9M | -$2.10 | -$132.3M | — | -1327.7% |
| FY2024 | — | -$115.9M | -$2.34 | -$90.4M | — | -651.5% |
| FY2023 | — | -$67.7M | -$1.65 | -$54.2M | — | -192.6% |
| FY2022 | — | -$53.0M | -$1.81 | -$48.8M | — | -490.4% |
| FY2021 | — | -$46.3M | -$1.80 | -$35.3M | — | 1085.1% |
| FY2020 | — | -$33.3M | — | -$27.4M | — | -26.9% |
| FY2019 | — | -$16.9M | — | -$16.7M | — | -26.5% |
| FY2018 | — | -$12.2M | — | — | — | 223.1% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Cabaletta Bio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cabaletta Bio, Inc. has historically struggled to out-earn its cost of capital, averaging just -8.4% ROIC.
Cabaletta Bio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Cabaletta Bio, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.